Gubra is a Danish biotech company specializing in peptide-based drug discovery and preclinical research for metabolic diseases such as obesity and diabetes. It combines a contract research organization (CRO) business that serves pharma and biotech clients with an internal pipeline of peptide therapeutics. The company is known for high-throughput peptide chemistry, animal models of metabolic disease, and partnered discovery programs.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 199.4 | — | 4.3 | — |
| 2023 | 205 | 2.8% | -44.5 | -1,133% |
| 2024 | 265.7 | 29.6% | -36.5 | — |
| 2025 | 2,636.8 | 892.3% | 1,690.6 | — |
All markets — KeepWinning global stock screener
Other companies on Copenhagen: NTG Nordic Transport Group A/S (NTG), Scandinavian Tobacco Group A/S (STG), Boozt AB (publ) (BOOZT DKK), SP Group A/S (SPG), Lån & Spar Bank A/S (LASP), Better Collective A/S (BETCO DKK)